Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate 1 MG BID for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo for smoking cessation.


Options:
A: Inclusion Criteria:

* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion Criteria:

* Subjects who have used bupropion, Zyban, or Wellbutrin previously.
B: Inclusion Criteria:

* Competent and mature
* Have diagnosed COPD \[spirometry verified and evaluated by pulmonary specialist\]
* Current daily smoker \[Minimum 1 cigarette daily\]
* Have smoked minimum 20 pack years (1 pack year = 20 cigarettes daily in 1 year)
* Want to or try to stop smoking
* Do not mind taking varenicline or NRT during the trial
* Are willing to give blood and urine samples according to the protocol

Exclusion Criteria:

* Previously included in the trial
* Hospitalized with COPD-exacerbation within the last 24 months
* Are associated with hospital outpatient clinic for COPD disease treatment
* Have FEV1\<50%.
* Pregnancy/breastfeeding
* Life expectancy less than 1 year
* Severe linguistic problems or inability to give informed consent
* Severe mental illness that is not controlled with medication
* Active alcohol or substance abuse
* Active cancer disease\* \*The person can participate if he or she has had a cancer disease that is now referred to as curative/radically treated. Basal cell carcinoma of the skin does not count as an exclusion criterion.
C: Inclusion Criteria:

The selection criteria for the clinical trial are designed to include a wide range of participants such that the study sample will be representative of the broader U.S. population of the Memphis metropolitan area. Those who might be at risk of adverse outcomes from the study interventions will be excluded (see exclusion criteria). All participants will give voluntary consent at the screening visit by signing an informed consent statement which has been approved by the Institutional Review Board (IRB). We will encourage the participation of women and minorities. The study will be open to all persons of any race or gender who are:

1. \*18 to 35 years old
2. BMI \> 22 kg / m2
3. Self report smoking \> 10 cigarettes each day
4. Have access to a telephone and the internet
5. Demonstrate ability to access a specific web site
6. Demonstrate ability to receive and respond to email
7. Willing to accept random assignment
8. \*Intending to be available for a 24 month intervention
9. \*At risk for weight gain (e.g. plan to quit smoking)

Exclusion Criteria:

Persons will be excluded from the TARGIT study for the following:

1. \*Current participation in a commercial weight loss program (e.g. Weight Watchers, Jenny Craig, etc.), current use of a prescription weight loss medication, planned weight loss surgery within the next 24 months (e.g. gastric bypass, lap band, or liposuction), current or planned enrollment in another diet / physical activity / weight loss study
2. Currently meet recommendations for physical activity (i.e., 30 minutes or more of moderate physical activity per day on the majority of days each week - 150 minutes or more each week)
3. \*History of cerebral, coronary, or peripheral vascular disease, or serious uncontrolled cardiac arrhythmia, revascularization procedure or uncontrolled congestive heart failure in the past 6 months
4. Current substance abuse (includes alcohol use in excess of 21 drinks a week)
5. Uncontrolled hypertension as defined as BP \> 140/90 mm Hg
6. Presence of an unstable psychiatric condition or use of anti-psychotic drugs
7. History of significant kidney disease or liver disease
8. History of uncontrolled thyroid disease or pheochromocytoma
9. Current use of a medication that may interfere with primary study endpoints (e.g. a weight loss medication such as Orlistat, etc) or that may increase the risk of side effects from the study intervention that can not be discontinued
10. Severe uncontrolled asthma, bronchitis, or emphysema that precludes exercise
11. Resting heart rate \> 100
12. \*Malignancy in the last 5 years (except non-melanoma skin cancer)
13. Plans to move from the Memphis metropolitan area in the next two years
14. Current participation in another clinical trial
15. \*Other medical or behavioral factors, that in the judgment of the Principal Investigator, may interfere with study participation or the ability to follow the intervention protocol
16. \*History of diabetes treated with a medication that may cause hypoglycemia such as insulin or an oral hypoglycemic agent
17. Known allergy or sensitivity to the nicotine patch
18. \*Currently pregnant or gave birth within the last 6 months, currently lactating or breast feeding within the last 3 months, actively planning pregnancy within the next 24 months
19. \*BMI \< 18.5 kg / m2 or \> 40 kg / m2
20. \*Have a household member on study staff
21. \*Current treatment for an eating disorder
22. \*Unable to provide informed consent
23. \*Regular use of a systemic steroids defined as taking the medication most days of the week
24. \*Use of medications to treat attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD)
D: Inclusion Criteria:

* Current male or female cigarette smokers who are motivated to stop smoking.
* Smoked an average of 10 cigarettes per day during past year and the month prior to first visit.

Exclusion Criteria:

* Patients who have used a nicotine replacement product, bupropion, clonidine or notriptyline within the past 6 months.
* Patients currently with depression or diagnosed with depression in past 12 months.
* Past or present history of psychosis, panic disorder, or bipolar disorder.

Answer: A